Skip to main content
Premium Trial:

Request an Annual Quote

HTG Validating PROOF Centre's Heart Transplant Rejection Assay

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today announced a collaboration to validate the Centre of Excellence for the Prevention of Organ Failure's (PROOF Centre) assay for organ rejection in heart transplant patients.

HTG will use the HTG Edge System in the clinical laboratory of St. Paul's Hospital, Providence Health Care in Vancouver, British Columbia to start clinical validation of the PROOF Centre's molecular biomarker test, which is intended to help physicians better monitor and treat patients after a heart transplant.

HTG's platform automates RNA analysis and delivers extraction-free, multiplexed results on a number of biological samples in 24 hours, the Tucson, Ariz.-based company said, adding the HTG Edge System enables the analysis of up to 47 different genes from minimal specimen volume.

The terms of the deal also call for the PROOF Centre to work with HTG to prepare for regulatory approval in North America. Funding for clinical validation of the assay is provided by the PROOF Centre, Genome British Columbia, Provincial Health Services Authority, Providence Health Care Research Institute, Vancouver Coastal Health Research Institute, and the Transplant Research Foundation of BC.

"This collaboration with PROOF will result in the timely and localized assessment of a patient's heart failure risk due to rejection," HTG CEO TJ Johnson said in a statement. "The marriage of HTG Edge RNA analysis platform and PROOF Centre's meticulous research will provide a testing mechanism to replace technology now available only at specialty laboratories."

Last November, HTG said it was licensing technology from the PROOF Centre to develop and commercialize a COPD test.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.